NASDAQ: ACXPAcurx Pharmaceuticals Inc Stock
$1.98-0.03 (-1.49%)
Updated Apr 24, 2026
ACXP Price
$1.98
Fair Value Price
N/A
Market Cap
$5.65M
52 Week Low
$1.33
52 Week High
$21.00
P/E
-0.37x
P/B
1.07x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$7.97M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.46
Operating Cash Flow
-$7M
Beta
0.67
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
ACXP Overview
Acurx Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company developing antibiotics to treat bacterial infections. Its lead candidate is ibezapolstat to treat patients with clostridium difficile infections. Acurx is also developing ACX-375C, a treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumoniae. Acurx Pharmaceuticals was incorporated in 2017 and is headquartered in Staten Island, NY.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine ACXP's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More
Zen Rating Component Grades
F
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
ACXP
Ranked#267 of 467
Ranked#267 of 467
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $23.57 | A | |
| $196.52 | A | |
| $7.54 | A |
Be the first to know about important ACXP news, forecast changes, insider trades & much more!
ACXP News
Overview
Due Diligence Score
–
Industry Average (25)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how ACXP scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ACXP is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
ACXP is good value based on its book value relative to its share price (1.07x), compared to the US Biotechnology industry average (4.94x)
P/B vs Industry Valuation
ACXP is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more ACXP due diligence checks available for Premium users.
Valuation
ACXP fair value
Fair Value of ACXP stock based on Discounted Cash Flow (DCF)
Price
$1.98
Fair Value
$4.35
Undervalued by
54.51%
ACXP is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
ACXP price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.37x
Industry
20.28x
Market
35.58x
ACXP price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.07x
Industry
4.94x
ACXP is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
ACXP's financial health
Profit margin
Revenue
$0.0
Net Income
-$1.6M
Profit Margin
0%
ACXP's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$7.7M
Liabilities
$2.4M
Debt to equity
0.46
ACXP's short-term assets ($7.69M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ACXP's short-term assets ($7.69M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ACXP's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
ACXP's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$1.2M
Investing
$0.0
Financing
$2.8M
ACXP's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
ACXP vs Biotech Stocks
Acurx Pharmaceuticals Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.